In people with T2D and/or metabolic syndrome, TZDs were shown to improve insulin sensitivity, reduce plasma-free fatty acids and triglycerides, and increase high-density cholesterol (HDL-C). The gene discussed is INS; the disease is type 2 diabetes mellitus.